(Q44899913)

7 December 2017

title

Ribavirin, but not interferon alpha-2b, is associated with impaired osteoblast proliferation and differentiation in vitro (English)

1 reference

7 December 2017

0 references

1 reference

R O Moreira

1

1 reference

7 December 2017

A Balduíno

2

1 reference

7 December 2017

H S L H Martins

3

1 reference

7 December 2017

J S N Reis

4

1 reference

7 December 2017

M E L Duarte

5

1 reference

7 December 2017

M L F Farias

6

1 reference

7 December 2017

R Borojevic

7

1 reference

7 December 2017

language of work or name

English

0 references

publication date

13 May 2004

1 reference

Calcified Tissue International

7 December 2017

published in

1 reference

7 December 2017

volume

75

1 reference

7 December 2017

issue

2

1 reference

7 December 2017

page(s)

160-168

1 reference

Treatment of chronic hepatitis

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Osteodystrophy in patients with chronic hepatitis and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

21 January 2018

Hepatic osteodystrophy.

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Lack of evidence for ribavirin-induced bone loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

A pharmacokinetic model for alpha interferon administered subcutaneously

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

Melatonin effects on bone: experimental facts and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

The genotoxic and cytotoxic effects of ribavirin in rat bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-004-0175-0

10.1007/S00223-004-0175-0

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference